Abstract
Introduction

65
Arterial thrombosis causes heart attacks and strokes and is one of the leading causes of morbidity 66 and mortality in the world. However, few adequate therapies are available for treating arterial 67 thrombosis. Protein Dislufide Isomerase (PDI), the founding member of a large family of thiol 68 oxydoreductases, was shown to be required for thrombosis, hemostasis and vascular 69 inflammation (Cho 2013) . PDI was discovered 50 years ago as the first folding catalyst. Since its 70 discovery, it was demonstrated that PDI acts as a dithiol-disulfide oxidoreductase capable of 71 reducing, oxidizing and isomerizing disulfide bonds. Independently of its redox activity, PDI can 72 also act as a chaperone both in vitro (Cai et al. 1994 ) and in vivo (McLaughlin & Bulleid 1998) . 
76
The catalytic domains a and a' contain catalytic CGHC motifs reacting with thiol groups in 77 substrate proteins. Non catalytic domains b and b' were shown to be involved in substrate 78 recognition and recruitment (Kozlov et al. 2010 ).
79
Although PDI is assisting newly synthesized proteins to fold in the endoplasmic reticulum (ER) 80 of majority of cells (Vaux et al. 1990 ), extracellular roles for PDI have been reported by previous 81 studies, namely in the initiation of thrombus formation (Cho et al. 2008 ). Upon vascular injury, 2010). All these data point towards PDI as valuable and emerging drug target for thrombosis.
89
Quercetin-3-Rutinoside, known also as Rutin, a flavonol glycoside derivative of Quercetin, was 90 previously described for displaying decent potency against PDI (IC 50 =6 μM), and it inhibited the 91 agonist-induced platelets aggregation at 30 μM (Jasuja et al. 2012) , however its utility is limited 92 by its low solubility and its off-target activity. Interestingly, a recent study demonstrated that Rutin inhibits PDI by binding directly to its b'x domain and not to the catalytic domains as 94 expected (Lin et al. 2015) , which revealed new insights into PDI inhibition mechanisms.
95
In an attempt to identify more potent, soluble and specific PDI inhibitors, we established an in 96 silico approach based on similarity search for Quercetin-similar compounds. A virtual screening 97 followed by Molecular Dynamics Simulation allowed the identification of 4 compounds that 98 were shown to form specific and stable complexes with PDI b'x domain and then could 99 constitute promising candidates for lead optimization in preventing arterial thrombosis.
100
Material and Methods
101
Ligand library preparation
102
A subset of 17,900,742 Drug-like compounds was obtained in SDF format from ZINC database
103
(http://zinc.docking.org/). The compounds were filtered according to Lipinsky's rule of five ( 104 MW <= 500, MW >= 150, XlogP <= 5, Rb <=7 and PSA < 150, Hbond_donors <= 5 ,
105
Hbond_acceptors <= 10) (Lipinski 2000 
120
Pocket analysis
121
Binding sites on PDI and Erp57 were analyzed using Pockets plugin for Vegazz software. generate protein-ligand complexes for molecular dynamics study and protein-ligand interactions.
140
A docking on ERp57 equivalent site was also performed for Rutin using the same approach as 141 for PDI.
142
Virtual Screening
143
Filtered compounds were subject to a first round docking to PDI b' domain using Autodock Vina centered on b' domain. A scoring function was established for compound ranking as follows:
Where E PDI are compound affinities for PDI b' domain, E Erp57 is compound affinity for Erp57 is 151 compound affinity, and E Rutin_Erp57 is Rutin affinity for Erp57.
152
Compounds were ranked according to the scoring function, a total of 23 were selected with 153 respective score higher than Rutin's score. Selected Hits were subject to Drug-likeness filtering 
162
Molecular Dynamics Simulation
163
Based on the docking results, molecular dynamics simulations were performed for PDI alone or 164 in complex with a total of 6 ligands; five of them were issued from the virtual screening 165 workflow, in addition to the previously described PDI inhibitor; Rutin (Jasuja et al. 2012 ). then to a counter screening on ERp57 b' domain for target selectivity.
197
Compounds were ranked according to the scoring function, a total of 23 were selected with 198 respective score higher than Rutin's score (see Table 1 ). Drug-likeness filtering was performed 199 using DruLito (Bickerton et al. 2012 ) and identified five molecules, listed in Table 3 . position in the C ring of quercetin-3-Rutinoside is critical for its ability to inhibit PDI (see Table   251 3). All analogs tested with a sugar in this position inhibited PDI, while analogs lacking this sugar 252 failed to demonstrate inhibition.
253
In order to investigate the binding effect of Rutin on PDI stability, we carried Molecular lower than PDI alone, in a similar way to Rutin (see Table 2 ). We believe that adding charged 299 groups on the benzyl group attached to piperazin may increase protein-ligand stability by 300 establishing polar bonds with charged residues harboring the binding pocket, and hence limits 301 protein flexibility and catalytic activity. Only one compound ZINC19632922 showed an increase 302 in RMSD (see Table 2 ) which can be due to benzo-furan group solvent exposure (see Figure 5 ).
303
This compound is a drug known as Befuraline, it was previously reported as inhibitor of 
Conclusion
307
In conclusion, we reported in this study new insights into PDI inhibition mechanism 308 through structure-activity relationship and molecular dynamics simulation of a reported PDI molecule and compared to Rutin fingerprint using RDkit Fingerprint similarity node.
410
Compounds showing a Tanimoto coefficient above 0.3 are selected and written in SDF format. 
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